Tower Research Capital (TRC)’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-3,953
| Closed | -$39.4K | – | 5417 |
|
|
2025
Q2 | $39.4K | Buy |
3,953
+2,299
| +139% | +$18.5K | ﹤0.01% | 3178 |
|
|
2025
Q1 | $9.87K | Sell |
1,654
-728
| -31% | -$5.34K | ﹤0.01% | 3712 |
|
|
2024
Q4 | $18.3K | Sell |
2,382
-2,788
| -54% | -$24K | ﹤0.01% | 3260 |
|
|
2024
Q3 | $52.8K | Sell |
5,170
-4,897
| -49% | -$74.7K | ﹤0.01% | 2694 |
|
|
2024
Q2 | $149K | Buy |
10,067
+197
| +2% | +$2.82K | ﹤0.01% | 2296 |
|
|
2024
Q1 | $135K | Sell |
9,870
-6,767
| -41% | -$73.7K | ﹤0.01% | 1660 |
|
|
2023
Q4 | $182K | Buy |
16,637
+13,989
| +528% | +$139K | ﹤0.01% | 2182 |
|
|
2023
Q3 | $29K | Buy |
2,648
+1,661
| +168% | +$21.2K | ﹤0.01% | 3052 |
|
|
2023
Q2 | $13.1K | Buy |
987
+89
| +10% | +$1.27K | ﹤0.01% | 3807 |
|
|
2023
Q1 | $12K | Buy |
898
+513
| +133% | +$9.19K | ﹤0.01% | 4089 |
|
|
2022
Q4 | $7K | Sell |
385
-10,061
| -96% | -$197K | ﹤0.01% | 4579 |
|
|
2022
Q3 | $199K | Buy |
10,446
+4,919
| +89% | +$113K | ﹤0.01% | 1936 |
|
|
2022
Q2 | $114K | Sell |
5,527
-328
| -6% | -$7.78K | ﹤0.01% | 2183 |
|
|
2022
Q1 | $189K | Buy |
5,855
+3,684
| +170% | +$134K | ﹤0.01% | 1772 |
|
|
2021
Q4 | $101K | Buy |
2,171
+1,608
| +286% | +$53.5K | ﹤0.01% | 2214 |
|
|
2021
Q3 | $15K | Sell |
563
-661
| -54% | -$17.3K | ﹤0.01% | 3981 |
|
|
2021
Q2 | $31K | Buy |
1,224
+21
| +2% | +$500 | ﹤0.01% | 3450 |
|
|
2021
Q1 | $41K | Buy |
1,203
+458
| +61% | +$16.6K | ﹤0.01% | 3289 |
|
|
2020
Q4 | $25K | Sell |
745
-1,234
| -62% | -$32.7K | ﹤0.01% | 3722 |
|
|
2020
Q3 | $49K | Buy |
+1,979
| New | +$53.2K | ﹤0.01% | 3550 |
|
Other funds holding ITOS
Tower Research Capital (TRC)'s ITOS Position: Q3 2025 in Review
Tower Research Capital (TRC) sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 3,953 shares — an estimated $39.4K sold.
Tower Research Capital (TRC) first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $199K in Q3 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Tower Research Capital (TRC) reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,953 iTeos Therapeutics shares in Q3 2025, an estimated $39.4K.
- Tower Research Capital (TRC) first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Tower Research Capital (TRC)'s iTeos Therapeutics position peaked at $199K in Q3 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.